Liver fibrosis tied to specific heart failure, regardless of HIV or hepatitis C status

March 06, 2020

(Boston)-- While there is an association between liver fibrosis and heart failure, the mechanisms for this association are currently unclear but may be of particular importance for people living with human immunodeficiency virus (HIV) and/or hepatitis C, both of which are chronic infections that affect the liver and heart.

Prior research has shown that people with a certain type of liver disease that involves scarring of the liver (fibrosis) have a higher risk of heart failure. Now these same researchers have discovered that this higher risk may be specific to a certain kind of heart failure called heart failure with preserved ejection fraction (HFpEF).

A multidisciplinary team, led by a researcher from Boston University School of Medicine (BUSM) grouped U.S. Veterans from the Veterans Aging Cohort Study (VACS) who had never had heart failure into three categories representing advanced fibrosis, indeterminate fibrosis, and no advanced fibrosis. They then observed these individuals until they experienced new onset heart failure or death and then estimated the rates and risk of heart failure across the three liver fibrosis groups.

"Our findings suggest that the link between liver fibrosis and heart failure may be specific to one type of heart failure (preserved ejection) and not heart failure with reduced ejection fraction," explained corresponding author Kaku So-Armah, PhD, assistant professor of medicine at BUSM.

According to the researchers, implications of this work include the need for ongoing research focusing on the role of liver fibrosis in new onset heart failure, particularly HFpEF. Further implications include the need to screen for and reduce heart failure risk among people with liver disease, particularly among people with conditions like HIV or hepatitis C that enhance the overall risk of heart failure.

"People with advanced liver fibrosis, including people without HIV or hepatitis C, may have increased risk for heart failure with preserved ejection fraction compared to people without evidence of advanced liver fibrosis. Preventing liver fibrosis, particularly among people already at high risk for heart failure, may be an important factor in preventing or reducing risk of heart failure with preserved ejection fraction; an idea to be tested in future studies."
-end-
The findings appear online in the journal Progress in CVD.

Funding for this study was provided by grant K01 HL1314701 and HL095136 from the National Heart, Lung, and Blood Institute and grants AA013566-10, AA020790, and AA020794 from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health. Dr. Long is supported in part by grant K23 DK113252 from the National Institute of Diabetes and Digestive and Kidney Diseases.

Editor's Note:

Joseph K. Lim has received consulting fees from Bristol-Myers Squibb and Gilead. Adeel A. Butt has received investigator initiated research grants (to the institution) from Gilead, Merck, and AbbVie. Vincent C. Marconi has received research grants from the Centers for Disease Control and Prevention and unrestricted grants and contracts from ViiV. Matthew J. Budoff has received research grants and contracts from General Electric.

Boston University School of Medicine

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.